Now showing items 1-3 of 3

    • CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. 

      Shenoy, TR; Boysen, G; Wang, MY; Xu, QZ; Guo, W; Koh, FM; Wang, C; Zhang, LZ; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, DN; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, DY; de Bono, J; Wu, H (2017-07-01)
      Background: Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized ...
    • Loss of Rb overrides the requirement for ERK activity for cell proliferation. 

      D'Abaco, GM; Hooper, S; Paterson, H; Marshall, CJ (2002-12)
      The Ras GTPase is a critical transducer of mitogenic signals ultimately leading to inactivation of the retinoblastoma (Rb) protein, but the molecular basis underlying Ras-dependent control of cell cycle kinetics remains ...
    • Mutational signatures of ionizing radiation in second malignancies. 

      Behjati, S; Gundem, G; Wedge, DC; Roberts, ND; Tarpey, PS; Cooke, SL; Van Loo, P; Alexandrov, LB; Ramakrishna, M; Davies, H; Nik-Zainal, S; Hardy, C; Latimer, C; Raine, KM; Stebbings, L; Menzies, A; Jones, D; Shepherd, R; Butler, AP; Teague, JW; Jorgensen, M; Khatri, B; Pillay, N; Shlien, A; Futreal, PA; Badie, C; ICGC Prostate Group; McDermott, U; Bova, GS; Richardson, AL; Flanagan, AM; Stratton, MR; Campbell, PJ (2016-09-12)
      Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched ...